Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production

Arthritis and Rheumatism

Volumn 62, Issue 7, 2010, Pages 2073-2085

  Amuro, Hideki ^a   Ito, Tomoki ^a   Miyamoto, Rie ^a   Sugimoto, Hiroyuki ^a   Torii, Yoshitaro ^a   Son, Yonsu ^a   Nakamichi, Naoto ^a   Yamazaki, Chihiro ^b,c   Hoshino, Katsuaki ^b   Kaisho, Tsuneyasu ^b,c,d   Ozaki, Yoshio ^a   Inaba, Muneo ^a   Amakawa, Ryuichi ^a   Fukuhara, Shirou ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b RIKEN Center for Integrative Medical Sciences   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INTERFERON REGULATORY FACTOR 7; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE P38; PITAVASTATIN; PROTEIN KINASE B; RHO KINASE INHIBITOR; SIMVASTATIN; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL ACTIVATION; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; INTRACELLULAR SIGNALING; MOLECULAR MECHANICS; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SYSTEMIC LUPUS ERYTHEMATOSUS;

CELLS, CULTURED; DENDRITIC CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 77954240134     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27478     Document Type: Article

References (50)

1. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7.
2. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:78-84.
3. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004;363:1607-8. (Pubitemid 38625664)
4. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001;21:115-21.
5. Lawman S, Mauri C, Jury EC, Cook HT, Ehrenstein MR. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol 2004;173:7641-6. (Pubitemid 39628206)
6. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006;6:358-70.
7. Tristano AG, Fuller K. Immunomodulatory effects of statins and autoimmune rheumatic diseases: novel intracellular mechanism involved. Int Immunopharmacol 2006;6:1833-46. (Pubitemid 44574489)
8. Ghittoni R, Napolitani G, Benati D, Ulivieri C, Patrussi L, Laghi Pasini F, et al. Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases. Eur J Immunol 2006;36:2885-93. (Pubitemid 44782562)
9. Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, Zamvil SS, et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 2006;203:401-12.
10. + lymphocytes. J Immunol 2008;180:6988-96.
11. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
12. Amano M, Fukata Y, Kaibuchi K. Regulation and functions of Rho-associated kinase. Exp Cell Res 2000;261:44-51.
13. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003;4:446-56. (Pubitemid 36648590)
14. Nagashima T, Okazaki H, Yudoh K, Matsuno H, Minota S. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum 2006;54:579-86. (Pubitemid 43228634)
15. Hillyard DZ, Cameron AJ, McIntyre AH, Hadden MH, Marshall HE, Johnston N, et al. Inhibition of proliferation and signalling mechanisms in human lymphocytes by fluvastatin. Clin Exp Pharmacol Physiol 2002;29:673-8. (Pubitemid 34779617)
16. Prasad R, Giri S, Nath N, Singh I, Singh AK. Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-κB pathway by lovastatin limits endothelial-monocyte cell interaction. J Neurochem 2005;94:204-14. (Pubitemid 40911406)
17. Ruperez M, Rodrigues-Diez R, Blanco-Colio LM, Sanchez-Lopez E, Rodriguez-Vita J, Esteban V, et al. HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways. Hypertension 2007;50:377-83.
18. Kadowaki N. The divergence and interplay between pDC and mDC in humans. Front Biosci 2009;14:808-17.
19. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005;23:275-306.
20. Ito T, Kanzler H, Duramad O, Cao W, Liu YJ. Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. Blood 2006;107:2423-31.
21. Ronnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008;17:394-9.
22. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 2001;294:1540-3.
23. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production. J Exp Med 2005;202:135-43.
24. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005;434:772-7.
25. Honda K, Yanai H, Mizutani T, Negishi H, Shimada N, Suzuki N, et al. Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc Natl Acad Sci U S A 2004;101:15416-21.
26. Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M, et al. Interferon-α induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 2004;5:1061-8.
27. Uematsu S, Sato S, Yamamoto M, Hirotani T, Kato H, Takeshita F, et al. Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-α induction. J Exp Med 2005;201:915-23.
28. Hoshino K, Sugiyama T, Matsumoto M, Tanaka T, Saito M, Hemmi H, et al. IκB kinase-α is critical for interferon-α production induced by Toll-like receptors 7 and 9. Nature 2006;440:949-53.
29. Liang SL, Liu H, Zhou A. Lovastatin-induced apoptosis in macrophages through the Rac1/Cdc42/JNK pathway. J Immunol 2006;177:651-6.
30. Yilmaz A, Reiss C, Weng A, Cicha I, Stumpf C, Steinkasserer A, et al. Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol 2006;79:529-38.
31. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
32. Osawa Y, Iho S, Takauji R, Takatsuka H, Yamamoto S, Takahashi T, et al. Collaborative action of NF-κB and p38 MAPK is involved in CpG DNA-induced IFN-α and chemokine production in human plasmacytoid dendritic cells. J Immunol 2006;177:4841-52.
33. Wolfrum S, Dendorfer A, Schutt M, Weidtmann B, Heep A, Tempel K, et al. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol 2004;44:348-55.
34. Bussolati B, Deregibus MC, Fonsato V, Doublier S, Spatola T, Procida S, et al. Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway. J Am Soc Nephrol 2005;16:1936-47.
35. Patel TR, Corbett SA. Simvastatin suppresses LPS-induced Akt phosphorylation in the human monocyte cell line THP-1. J Surg Res 2004;116:116-20.
36. Holschermann H, Schuster D, Parviz B, Haberbosch W, Tillmanns H, Muth H. Statins prevent NF-κB transactivation independently of the IKK-pathway in human endothelial cells. Atherosclerosis 2006;185:240-5.
37. Vincent L, Soria C, Mirshahi F, Opolon P, Mishal Z, Vannier JP, et al. Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler Thromb Vasc Biol 2002;22:623-9.
38. Fukuyama R, Fujita T, Azuma Y, Hirano A, Nakamuta H, Koida M, et al. Statins inhibit osteoblast migration by inhibiting Rac-Akt signaling. Biochem Biophys Res Commun 2004;315:636-42. (Pubitemid 38229391)
39. Cerezo-Guisado MI, Garcia-Marin LJ, Lorenzo MJ, Bragado MJ. Lovastatin inhibits the growth and survival pathway of phosphoinositide 3-kinase/protein kinase B in immortalized rat brain neuroblasts. J Neurochem 2005;94:1277-87.
40. Guiducci C, Ghirelli C, Marloie-Provost MA, Matray T, Coffman RL, Liu YJ, et al. PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. J Exp Med 2008;205:315-22. (Pubitemid 351281597)
41. O'Keeffe M, Grumont RJ, Hochrein H, Fuchsberger M, Gugasyan R, Vremec D, et al. Distinct roles for the NF-κB1 and c-Rel transcription factors in the differentiation and survival of plasmacytoid and conventional dendritic cells activated by TLR-9 signals. Blood 2005;106:3457-64. (Pubitemid 41609181)
42. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008;14:37-44.
43. Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004;50:1861-72. (Pubitemid 38725099)
44. Cederblad B, Blomberg S, Vallin H, Perers A, Alm GV, Ronnblom L. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-α producing cells. J Autoimmun 1998;11:465-70. (Pubitemid 28520202)
45. Zeuner RA, Klinman DM, Illei G, Yarboro C, Ishii KJ, Gursel M, et al. Response of peripheral blood mononuclear cells from lupus patients to stimulation by CpG oligodeoxynucleotides. Rheumatology (Oxford) 2003;42:563-9.
46. Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, Gonzalez-Amaro R. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 2003;12:607-11. (Pubitemid 37021796)
47. Ehrenstein MR, McSweeney E, Swana M, Worman CP, Goldstone AH, Isenberg DA. Appearance of anti-DNA antibodies in patients treated with interferon-α. Arthritis Rheum 1993;36:279-80. (Pubitemid 23059344)
48. Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol 2002;107:133-44. (Pubitemid 34455077)
49. Ghittoni R, Patrussi L, Pirozzi K, Pellegrini M, Lazzerini PE, Capecchi PL, et al. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J 2005;19:605-7.
50. Iparraguirre A, Tobias JW, Hensley SE, Masek KS, Cavanagh LL, Rendl M, et al. Two distinct activation states of plasmacytoid dendritic cells induced by influenza virus and CpG 1826 oligonucleotide. J Leukoc Biol 2008;83:610-20.